About QuidelOrtho Corporation
https://www.quidelortho.comQuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units.
CEO
Brian J. Blaser
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 195
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:11.01M
Value:$378.16M
BLACKROCK, INC.
Shares:10.22M
Value:$350.96M
VANGUARD GROUP INC
Shares:7.64M
Value:$262.23M
Summary
Showing Top 3 of 288
About QuidelOrtho Corporation
https://www.quidelortho.comQuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $699.9M ▲ | $1.36B ▲ | $-733M ▼ | -104.73% ▼ | $-10.78 ▼ | $-598.7M ▼ |
| Q2-2025 | $615.1M ▼ | $228.8M ▼ | $-255.4M ▼ | -41.52% ▼ | $-3.77 ▼ | $-73.2M ▼ |
| Q1-2025 | $692.8M ▼ | $310.7M ▼ | $-12.7M ▲ | -1.83% ▲ | $-0.19 ▲ | $140.6M ▲ |
| Q4-2024 | $707.8M ▼ | $426.5M ▲ | $-178.4M ▼ | -25.2% ▼ | $-2.28 ▼ | $13.1M ▼ |
| Q3-2024 | $727.1M | $337.3M | $-19.9M | -2.74% | $-0.3 | $133.8M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $98.1M ▼ | $5.68B ▼ | $3.64B ▲ | $2.04B ▼ |
| Q2-2025 | $151.7M ▲ | $6.38B ▼ | $3.59B ▲ | $2.79B ▼ |
| Q1-2025 | $127.1M ▲ | $6.46B ▲ | $3.46B ▲ | $3B ▲ |
| Q4-2024 | $98.3M ▼ | $6.42B ▼ | $3.44B ▼ | $2.98B ▼ |
| Q3-2024 | $143.7M | $6.8B | $3.61B | $3.19B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-733M ▼ | $-45.5M ▲ | $-53.9M ▼ | $46M ▼ | $-53.6M ▼ | $-94.7M ▼ |
| Q2-2025 | $-255.4M ▼ | $-46.8M ▼ | $-33M ▲ | $103.3M ▲ | $24.5M ▼ | $-40.3M ▼ |
| Q1-2025 | $-12.7M ▲ | $65.6M ▲ | $-56.2M ▼ | $17.6M ▲ | $28.7M ▲ | $75.7M ▲ |
| Q4-2024 | $-178.4M ▼ | $63.7M ▼ | $-37.9M ▲ | $-68.9M ▼ | $-45.5M ▼ | $16.5M ▼ |
| Q3-2024 | $-19.9M | $117.9M | $-56.5M | $-26.3M | $36.5M | $71.4M |
Revenue by Products
| Product | Q4-2023 | Q1-2024 | Q2-2024 | Q3-2024 |
|---|---|---|---|---|
 Other | $240.00M ▲ | $120.00M ▼ | $120.00M ▲ | $130.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 China Segment | $0 ▲ | $70.00M ▲ | $80.00M ▲ | $80.00M ▲ |
 EMEA Segment | $90.00M ▲ | $90.00M ▲ | $90.00M ▲ | $90.00M ▲ |
 North America Segment | $400.00M ▲ | $410.00M ▲ | $310.00M ▼ | $380.00M ▲ |
CEO
Brian J. Blaser
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 195
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:11.01M
Value:$378.16M
BLACKROCK, INC.
Shares:10.22M
Value:$350.96M
VANGUARD GROUP INC
Shares:7.64M
Value:$262.23M
Summary
Showing Top 3 of 288